Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles H Yoon

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Communications Medicine|July 2, 2024
High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistanceYu-Hwa Huang, Charles H Yoon, Amit Gandhi, et al.
Immunity|October 12, 2022
Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune responseSophia Liu, J Bryan Iorgulescu, Shuqiang Li, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2023
Slide-tags: scalable, single-nucleus barcoding for multi-modal spatial genomicsAndrew J C Russell, Jackson A Weir, Naeem M Nadaf, et al.
Nature|December 13, 2023
Slide-tags enables single-nucleus barcoding for multimodal spatial genomicsAndrew J C Russell, Jackson A Weir, Naeem M Nadaf, et al.
Cancer Cell|May 10, 2022
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomesAbhinav Jaiswal, Akanksha Verma, Ruth Dannenfelser, et al.
Future Oncology (London, England)|December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanomaJason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Cancer Immunology Research|April 11, 2025
First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Metastatic Melanoma PatientsF Stephen Hodi, Anita Giobbie-Hurder, Kwasi Adu-Berchie, et al.
Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Cancer Discovery|May 7, 2020
Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 BlockadeCécile Gstalder, David Liu, Diana Miao, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Communications Medicine|July 2, 2024
High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistanceYu-Hwa Huang, Charles H Yoon, Amit Gandhi, et al.
Immunity|October 12, 2022
Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune responseSophia Liu, J Bryan Iorgulescu, Shuqiang Li, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2023
Slide-tags: scalable, single-nucleus barcoding for multi-modal spatial genomicsAndrew J C Russell, Jackson A Weir, Naeem M Nadaf, et al.
Nature|December 13, 2023
Slide-tags enables single-nucleus barcoding for multimodal spatial genomicsAndrew J C Russell, Jackson A Weir, Naeem M Nadaf, et al.
Cancer Cell|May 10, 2022
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomesAbhinav Jaiswal, Akanksha Verma, Ruth Dannenfelser, et al.
Future Oncology (London, England)|December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanomaJason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Cancer Immunology Research|April 11, 2025
First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Metastatic Melanoma PatientsF Stephen Hodi, Anita Giobbie-Hurder, Kwasi Adu-Berchie, et al.
Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Cancer Discovery|May 7, 2020
Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 BlockadeCécile Gstalder, David Liu, Diana Miao, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
Pageof 5